Glaukos Co. (NYSE:GKOS) Director Sells $288,020.00 in Stock

Glaukos Co. (NYSE:GKOS) Director Gilbert H. Kliman sold 2,000 shares of the firm’s stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $144.01, for a total value of $288,020.00. Following the completion of the transaction, the director now owns 32,336 shares in the company, valued at $4,656,707.36. This represents a 5.82 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Glaukos Stock Down 1.1 %

NYSE:GKOS traded down $1.50 on Friday, hitting $138.82. 609,996 shares of the company’s stock were exchanged, compared to its average volume of 569,477. The firm has a 50-day moving average price of $136.25 and a 200-day moving average price of $126.81. Glaukos Co. has a 52 week low of $65.00 and a 52 week high of $147.65. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.71. The company has a market cap of $7.65 billion, a P/E ratio of -45.97 and a beta of 1.03.

Glaukos (NYSE:GKOS) last posted its quarterly earnings results on Monday, November 4th. The medical instruments supplier reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.20. The firm had revenue of $96.70 million during the quarter, compared to the consensus estimate of $91.50 million. Glaukos had a negative return on equity of 18.99% and a negative net margin of 42.43%. The business’s revenue was up 23.9% compared to the same quarter last year. During the same period last year, the company earned ($0.50) earnings per share. As a group, analysts expect that Glaukos Co. will post -1.89 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Values First Advisors Inc. bought a new position in Glaukos during the third quarter worth about $25,000. Harvest Fund Management Co. Ltd raised its stake in Glaukos by 2,263.2% in the third quarter. Harvest Fund Management Co. Ltd now owns 898 shares of the medical instruments supplier’s stock valued at $117,000 after buying an additional 860 shares during the period. Fifth Third Wealth Advisors LLC acquired a new position in shares of Glaukos during the 2nd quarter worth approximately $187,000. KBC Group NV raised its stake in Glaukos by 16.2% in the 3rd quarter. KBC Group NV now owns 1,445 shares of the medical instruments supplier’s stock valued at $188,000 after acquiring an additional 201 shares during the period. Finally, Brighton Jones LLC bought a new stake in Glaukos in the 2nd quarter valued at $208,000. Institutional investors own 99.04% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on GKOS. Morgan Stanley cut shares of Glaukos from an “equal weight” rating to an “underweight” rating and set a $120.00 price objective for the company. in a report on Monday, December 2nd. Stifel Nicolaus upped their price objective on shares of Glaukos from $145.00 to $153.00 and gave the company a “buy” rating in a research report on Monday, December 2nd. Citigroup upgraded Glaukos from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $132.00 to $162.00 in a report on Wednesday. Piper Sandler set a $140.00 price target on Glaukos in a report on Thursday, October 17th. Finally, UBS Group initiated coverage on Glaukos in a report on Friday, December 6th. They set a “buy” rating and a $182.00 price objective on the stock. One research analyst has rated the stock with a sell rating, two have issued a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $143.17.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.